#RedChip
JMIR Pediatrics: #Parent Anxiety and Response to a Telehealth Intervention for Hypoglycemia Fear: Secondary Analysis of a Randomized Trial
#Parent Anxiety and Response to a Telehealth Intervention for Hypoglycemia Fear: Secondary Analysis of a Randomized Trial
Background: #Parents of young #Children with type 1 diabetes (T1D) frequently report fear of hypoglycemia (FH), which can impact their diabetes management. REDCHiP (Reducing Emotional Distress for #Childhood Hypoglycemia in #Parents) is a telehealth-delivered cognitive behavioral intervention shown to reduce FH, but less is known about which #Parents benefit most. Objective: This secondary analysis examined whether pretreatment #Parent anxiety moderated REDCHiP’s effects and explored responder patterns by intervention arm and pretreatment anxiety. Methods: This was a secondary analysis of a large, randomized clinical trial comparing REDCHiP to an attention control condition (ATTN). We assessed outcomes before treatment (time 1) and 3 months after treatment (time 3). Our primary outcome was #Parental FH at time 3, adjusted for time 1 FH. The original trial used validated measures of #Parent FH and general anxiety. We evaluated #Parent anxiety at time 1 as both a categorical variable (clinically elevated or not) and a continuous variable (centered). We defined responders as #Parents achieving a reduction of ≥0.5 SDs in FH from time 1 to time 3. An analysis of covariance tested the treatment arm by anxiety interaction, with sensitivity analyses modeling anxiety continuously. Results: There was no significant treatment arm by anxiety interaction when modeling #Parent anxiety as either a categorical or continuous variable (>.05). However, exploratory analyses found that the adjusted mean time 3 FH was numerically lower among REDCHiP #Parents than ATTN #Parents with clinically elevated anxiety. Among #Parents with elevated anxiety, 78.6% (22/28) of REDCHiP #Parents met our responder criterion compared with 47.4% (9/19) of ATTN #Parents. Among #Parents with elevated anxiety, the adjusted odds of meeting the responder criterion were higher for REDCHiP than ATTN #Parents (odds ratio 6.35, 95% CI 1.47‐29.00). Conclusions: While time 1 #Parent anxiety did not significantly moderate treatment response, exploratory analyses suggested a potentially meaningful pattern among #Parents with clinically elevated anxiety. As telehealth-delivered behavioral interventions expand in #Pediatric type 1 diabetes care, secondary analyses of participant characteristics may help guide targeted implementation and enhance treatment benefit. Trial Registration: ClinicalTrials.gov NCT03914547; https://clinicaltrials.gov/study/NCT03914547
dlvr.it
November 3, 2026 at 6:54 PM
Vector Science and Therapeutics Corp. Signs Agreement with RedChip for Investor Relations Support#Investor_Relations#RedChip#Vector_Science
Vector Science and Therapeutics Corp. Signs Agreement with RedChip for Investor Relations Support
Vector Science and Therapeutics Corp. has entered into a strategic investor relations agreement with RedChip Companies to enhance its outreach and communication.
third-news.com
August 26, 2026 at 12:39 AM
Bimergen Energy partners with RedChip Companies to accelerate investor relations strategy in rapidly growing battery storage market, targeting 2.0 GW project portfolio #EnergyStorage #RenewableEnergy
September 22, 2025 at 6:18 PM
#CBDW RedChip Companies, will feature CBDW's CEO, Austen Lambrecht, who will share insight into the Company's innovative product portfolio and near-term expansion plans. Q/A webinar October 10, 2024, at 4:15 p.m. ET.
finance.yahoo.com/news/join-16...
Join 1606 Corp.'s Exclusive Live Investor Webinar and Q&A Session on October 10th
SEATTLE, WA / ACCESSWIRE / October 7, 2024 /1606 Corp. (OTC PINK:CBDW) (the "Company," "1606," or "CBDW"), a leader in innovative AI chatbot solutions, is pleased to invite investors to a webinar on O...
finance.yahoo.com
October 7, 2024 at 1:50 PM